Tailored Exercise Interventions to Reduce Fatigue in Cancer Survivors
Primary Purpose
Cancer-related Fatigue
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Traditional Exercise
Tailored Exercise
Sponsored by
About this trial
This is an interventional treatment trial for Cancer-related Fatigue
Eligibility Criteria
Inclusion Criteria:
- Aged between 18 and 75 years;
- Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score ≤ 34;
- Completion of treatment in ≥ 3 months and ≤ 5 years preceding enrollment;
- Approval received from personal physician and/or a Canadian Society for Exercise Physiology-Clinical Exercise Physiologist (CSEP-CEP);
- Command of the English language.
Exclusion Criteria:
- Contraindication to experimental procedures including transcranial magnetic stimulation (TMS);
- Diagnosed as having obstructive sleep apnea or anemia;
- Currently participating in a structured exercise intervention;
- Participant is pregnant.
Sites / Locations
- University of Calgary
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Traditional Exercise
Tailored Exercise
Arm Description
A classical exercise intervention based on current guidelines for cancer survivors.
A tailored and individualized exercise intervention based on the results of pre-intervention testing.
Outcomes
Primary Outcome Measures
Assessment of change in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Scale
Self-report questionnaire for the assessment of cancer-related fatigue.
Secondary Outcome Measures
Assessment of change in The Functional Assessment of Cancer Therapy - General (FACT-G)
General quality of life instrument intended for use with a variety of chronic illness conditions.
Assessment of change in Edmonton Symptom Assessment System-revised tiredness scale
Self-report questionnaire for the assessment of of nine common symptoms experienced by cancer patients.
Maximal Isometric Force in the Knee Extensors
A reduction in maximal isometric force in the knee extensors measured before, during and after an intermittent cycling test.
Cortical Voluntary Activation
A reduction voluntary activation (using transcranial magnetic stimulation) measured measured before, during and after an intermittent cycling test.
Voluntary Activation
A reduction voluntary activation (using femoral nerve stimulation) measured before, during and after an intermittent cycling test.
Potentiated Doublet Twitch Force
A reduction in potentiated quadriceps twitch force (from a high frequency doublet at 100 Hz) measured before, before, during and after an intermittent cycling test.
Muscle Compound Action Potential (M-Wave) Peak-to Peak Amplitude
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
Muscle Compound Action Potential (M-Wave) Peak-to Peak Duration
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
Muscle Compound Action Potential (M-Wave) Area
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
Motor Evoked Potential (MEP) Peak-to Peak Amplitude
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
Motor Evoked Potential (MEP) Peak-to Peak Duration
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
Motor Evoked Potential (MEP) Area
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
Cortical Silent Period
Evoked from TMS and measured (from stimulation artifact to the continuous resumption of EMG) before, during and after an intermittent cycling test.
Voluntary Electromyography (EMG)
Root mean square of the EMG signal during an MVC, measured before, during and after an intermittent cycling test.
Amplitude of the Sleep-Wake Cycle
The mean difference between lowest and highest activity period, recorded with actigraphy.
Peak Time of the sleep-wake Cycle
Time of day of the highest estimated level of wake, recorded by actigraphy.
Mesor of the Sleep-Wake Cycle
Mean level of activity over 24 hours, recorded with actigraphy.
inter-daily stability
the degree of regularity of the rest-activity patterns on individual days in the 24 h environment, recorded with actigraphy.
intra-daily variability
the fragmentation of periods of rest and activity, recorded with actigraphy.
L5
The mean activity counts in the least active 5 h period in the average 24 h pattern) recorded with actigraphy.
L5 mid
The central time of the L5 period, usually referring to the through of the activity period), recorded with actigraphy.
Wake actigraphy
Amount of activity during wake, recorded with actigraphy
Sleep Activity
Amount of activity during sleep periods, recorded with actigraphy
Activity Index
Percentage of activity per epoch for wake and sleep, recorded with actigraphy.
Time in bed
Time spent between the moment subject turn off the light to sleep and the moment he gets up, recorded with actigraphy.
Actual Sleep Time
Time spent asleep during the night, recorded with actigraphy.
Actual Wake Time
Time spent awaken during the night, recorded with actigraphy.
Sleep Onset Latency
Time to fall asleep, recorded with actigraphy.
Sleep Efficiency
Ratio between the time spent asleep and the total duration of sleep period, recorded with actigraphy.
Fragmentation index
Indication of the sleep quality based on movement during night, recorded with actigraphy.
Blood Biomarkers
Blood count, catecholamines, serotonin, cortisol, inflammatory markers and markers of oxidative stress.
Assessment of change in the Centre for Epidemiological Studies Depression Scale (CES-D) questionnaire.
Self-report questionnaire for the assessment of health-related quality of life, specific to cancer type.
Assessment of change in The Social Prevision Scale (SPS)
Self-report questionnaire for the assessment of social support.
Assessment of change in The Functional Assessment of Cancer Therapy (FACT) Cancer Specific
Self-report questionnaire for the assessment
Assessment of change in The Modified-Godin Leisure Time Exercise Questionnaire (GLTEQ)
Self-report questionnaire for the assessment of leisure time physical activity.
Assessment of change in The Insomnia Severity Index (ISI)
Self-report questionnaire for the assessment of insomnia severity.
Assessment of change in The Brief Pain Inventory Short Form (BPI-sf)
Self-report questionnaire for the assessment of pain.
Assessment of change in Maximal Oxygen Uptake
The highest 30 second average oxygen uptake measured during an an incremental cycling test.
Assessment of change in Muscle Cross-Sectional Area
Ultrasound measurement of the vastus lateralis and rectus femoris.
Heart Rate Variability
Variation in the time interval between heartbeats.
Assessment of change in Fat Mass
Measured using dual energy X-ray absorptiometry (DXA).
Assessment of change in Fat Free Mass
Measured using dual energy X-ray absorptiometry (DXA).
Assessment of change in Bone Mineral Density
Measured using dual energy X-ray absorptiometry (DXA).
Full Information
NCT ID
NCT03049384
First Posted
February 3, 2017
Last Updated
October 8, 2021
Sponsor
University of Calgary
Collaborators
Canadian Cancer Society (CCS)
1. Study Identification
Unique Protocol Identification Number
NCT03049384
Brief Title
Tailored Exercise Interventions to Reduce Fatigue in Cancer Survivors
Official Title
Tailored Exercise Interventions to Reduce Fatigue in Cancer Survivors
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
March 9, 2017 (Actual)
Primary Completion Date
March 31, 2020 (Actual)
Study Completion Date
March 31, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Calgary
Collaborators
Canadian Cancer Society (CCS)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Cancer-related fatigue (CRF) is a common and distressing symptom of cancer and/or cancer treatment that can persist for months or years in cancer survivors. Exercise is beneficial for the management of CRF, and general exercise guidelines for cancer survivors are available. However, exercise interventions have not been tailored to alleviate CRF in fatigued cancer survivors, and thus the potential to alleviate CRF may not have been realized. The primary aim of this research is to investigate the effect of a traditional vs. tailored 12-week exercise intervention on self-reported CRF severity.
Detailed Description
Background and Rationale
Approximately one-third of cancer survivors experience severe and persistent fatigue for a number of years post-treatment, but this distressing symptom is often under-treated by healthcare professionals due to a lack of mechanism-targeted interventions. The assessment of cancer-related fatigue (CRF) is reliant on subjective fatigue measurements such as self-report questionnaires. Less attention has been given to objective physiological measurements. However, there are well-established techniques which allow the assessment of neuromuscular fatigue and its peripheral and central origins which could be utilized in the study of CRF. Very few studies have considered these objective measures alongside self-report scales in the study of CRF and only two have used such techniques in cancer survivors. To date, no studies have investigated neuromuscular fatigue in whole body, dynamic activity as relevant to daily tasks (and involving the lower limb due to its functional relevance to locomotion). Novel testing developed in our laboratory could be used as part of a wider screening to develop individualized interventions to alleviate CRF. It is well accepted in the field that CRF is multidimensional and in addition to a potential neuromuscular component, the role of sleep disturbance may also be implicated. Interventions targeted at improving sleep quality are therefore warranted, and there is sound evidence for the efficacy of exercise interventions in particular for improving CRF in cancer survivors. As a non-pharmacological intervention, physical activity has the strongest evidence base for treating CRF. However, the mechanisms explaining the reduction of CRF with exercise are not understood. Due to the complex and multi-factorial nature of CRF, it would be of benefit to tailor exercise interventions to the specific deficits (in regards to neuromuscular mechanisms) or difficulties (for example sleep disturbance) experienced by the individual. Ultimately, mechanism-targeted exercise interventions could be translated to clinical rehabilitation programs and lead to an improved quality of for cancer survivors.
Research Question & Objectives
The primary aim of this research is to investigate the effect of a traditional vs. tailored 12-week exercise intervention on self-reported CRF severity.
Methods
Fatigued cancer survivors who have completed primary treatment ≥ 3 months and ≤ 5 years from enrollment will be randomly allocated to one of two treatment arms: traditional (active control) and tailored exercise. Participants in the traditional exercise group will engage in aerobic and resistance exercise that is consistent with published recommendations. The tailored exercise group will be prescribed an intervention designed to address individual deficits (identified at baseline) that may be related to CRF. Participants will be assessed before and after the intervention for patient-reported outcomes, neuromuscular function and fatigue in response to whole-body exercise, sleep quantity and quality, physical activity levels, cardiorespiratory fitness and blood biomarkers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer-related Fatigue
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants are assigned to one of two groups in parallel for the duration of the study.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Traditional Exercise
Arm Type
Active Comparator
Arm Description
A classical exercise intervention based on current guidelines for cancer survivors.
Arm Title
Tailored Exercise
Arm Type
Experimental
Arm Description
A tailored and individualized exercise intervention based on the results of pre-intervention testing.
Intervention Type
Other
Intervention Name(s)
Traditional Exercise
Intervention Description
The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
Intervention Type
Other
Intervention Name(s)
Tailored Exercise
Intervention Description
The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
Primary Outcome Measure Information:
Title
Assessment of change in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Scale
Description
Self-report questionnaire for the assessment of cancer-related fatigue.
Time Frame
Baseline to after the 12-week intervention, at 6 month and 12 month follow up.
Secondary Outcome Measure Information:
Title
Assessment of change in The Functional Assessment of Cancer Therapy - General (FACT-G)
Description
General quality of life instrument intended for use with a variety of chronic illness conditions.
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in Edmonton Symptom Assessment System-revised tiredness scale
Description
Self-report questionnaire for the assessment of of nine common symptoms experienced by cancer patients.
Time Frame
Baseline and after the 12-week intervention, and during follow up (6 and 12 months).
Title
Maximal Isometric Force in the Knee Extensors
Description
A reduction in maximal isometric force in the knee extensors measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Cortical Voluntary Activation
Description
A reduction voluntary activation (using transcranial magnetic stimulation) measured measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Voluntary Activation
Description
A reduction voluntary activation (using femoral nerve stimulation) measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Potentiated Doublet Twitch Force
Description
A reduction in potentiated quadriceps twitch force (from a high frequency doublet at 100 Hz) measured before, before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Muscle Compound Action Potential (M-Wave) Peak-to Peak Amplitude
Description
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Muscle Compound Action Potential (M-Wave) Peak-to Peak Duration
Description
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Muscle Compound Action Potential (M-Wave) Area
Description
Evoked from supra-maximal stimulation of the femoral nerve and measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Motor Evoked Potential (MEP) Peak-to Peak Amplitude
Description
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Motor Evoked Potential (MEP) Peak-to Peak Duration
Description
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Motor Evoked Potential (MEP) Area
Description
Normalized to the maximal M-wave and measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Cortical Silent Period
Description
Evoked from TMS and measured (from stimulation artifact to the continuous resumption of EMG) before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Voluntary Electromyography (EMG)
Description
Root mean square of the EMG signal during an MVC, measured before, during and after an intermittent cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Amplitude of the Sleep-Wake Cycle
Description
The mean difference between lowest and highest activity period, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Peak Time of the sleep-wake Cycle
Description
Time of day of the highest estimated level of wake, recorded by actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Mesor of the Sleep-Wake Cycle
Description
Mean level of activity over 24 hours, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
inter-daily stability
Description
the degree of regularity of the rest-activity patterns on individual days in the 24 h environment, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
intra-daily variability
Description
the fragmentation of periods of rest and activity, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
L5
Description
The mean activity counts in the least active 5 h period in the average 24 h pattern) recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
L5 mid
Description
The central time of the L5 period, usually referring to the through of the activity period), recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Wake actigraphy
Description
Amount of activity during wake, recorded with actigraphy
Time Frame
Baseline and after the 12-week intervention.
Title
Sleep Activity
Description
Amount of activity during sleep periods, recorded with actigraphy
Time Frame
Baseline and after the 12-week intervention.
Title
Activity Index
Description
Percentage of activity per epoch for wake and sleep, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Time in bed
Description
Time spent between the moment subject turn off the light to sleep and the moment he gets up, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Actual Sleep Time
Description
Time spent asleep during the night, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Actual Wake Time
Description
Time spent awaken during the night, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Sleep Onset Latency
Description
Time to fall asleep, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Sleep Efficiency
Description
Ratio between the time spent asleep and the total duration of sleep period, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Fragmentation index
Description
Indication of the sleep quality based on movement during night, recorded with actigraphy.
Time Frame
Baseline and after the 12-week intervention.
Title
Blood Biomarkers
Description
Blood count, catecholamines, serotonin, cortisol, inflammatory markers and markers of oxidative stress.
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in the Centre for Epidemiological Studies Depression Scale (CES-D) questionnaire.
Description
Self-report questionnaire for the assessment of health-related quality of life, specific to cancer type.
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in The Social Prevision Scale (SPS)
Description
Self-report questionnaire for the assessment of social support.
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in The Functional Assessment of Cancer Therapy (FACT) Cancer Specific
Description
Self-report questionnaire for the assessment
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in The Modified-Godin Leisure Time Exercise Questionnaire (GLTEQ)
Description
Self-report questionnaire for the assessment of leisure time physical activity.
Time Frame
Baseline, after the 12-week intervention, and during follow up (6 and 12 months).
Title
Assessment of change in The Insomnia Severity Index (ISI)
Description
Self-report questionnaire for the assessment of insomnia severity.
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in The Brief Pain Inventory Short Form (BPI-sf)
Description
Self-report questionnaire for the assessment of pain.
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in Maximal Oxygen Uptake
Description
The highest 30 second average oxygen uptake measured during an an incremental cycling test.
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in Muscle Cross-Sectional Area
Description
Ultrasound measurement of the vastus lateralis and rectus femoris.
Time Frame
Baseline and after the 12-week intervention.
Title
Heart Rate Variability
Description
Variation in the time interval between heartbeats.
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in Fat Mass
Description
Measured using dual energy X-ray absorptiometry (DXA).
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in Fat Free Mass
Description
Measured using dual energy X-ray absorptiometry (DXA).
Time Frame
Baseline and after the 12-week intervention.
Title
Assessment of change in Bone Mineral Density
Description
Measured using dual energy X-ray absorptiometry (DXA).
Time Frame
Baseline and after the 12-week intervention.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Aged between 18 and 75 years;
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score ≤ 34;
Completion of treatment in ≥ 3 months and ≤ 5 years preceding enrollment;
Approval received from personal physician and/or a Canadian Society for Exercise Physiology-Clinical Exercise Physiologist (CSEP-CEP);
Command of the English language.
Exclusion Criteria:
Contraindication to experimental procedures including transcranial magnetic stimulation (TMS);
Diagnosed as having obstructive sleep apnea or anemia;
Currently participating in a structured exercise intervention;
Participant is pregnant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillaume Millet, PhD
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Calgary
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 1N4
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30041626
Citation
Twomey R, Martin T, Temesi J, Culos-Reed SN, Millet GY. Tailored exercise interventions to reduce fatigue in cancer survivors: study protocol of a randomized controlled trial. BMC Cancer. 2018 Jul 24;18(1):757. doi: 10.1186/s12885-018-4668-z.
Results Reference
derived
Learn more about this trial
Tailored Exercise Interventions to Reduce Fatigue in Cancer Survivors
We'll reach out to this number within 24 hrs